Omeprazole Powder for Injection 40mg

Omeprazole Injection 40mg | Proton Pump Inhibitor
  • Dosage: Omeprazole 40mg
  • Volume:  7 ml Vail
  • Packaging: 7ml vials * 10/tray/box*300 carton
  • Shelf Life: 24 months 

Click to add this item to cart.

Product Description

Product NameOmeprazole Powder for Injection
Specification40mg per vial
Dosage FormSterile Lyophilized Powder for Solution for Intravenous Injection / Infusion
Active IngredientOmeprazole (as Omeprazole Sodium)
Pharmacological ClassProton Pump Inhibitor (PPI) / Gastric Acid Secretion Inhibitor
Route of AdministrationIntravenous injection (slow, over at least 2 to 5 minutes), or intravenous infusion (after further dilution, over 20 to 30 minutes). NOT for intramuscular or subcutaneous injection.
Packaging40mg lyophilized powder in glass vial with rubber stopper and aluminum flip-off cap
StorageStore below 25°C, protected from light and moisture. Do not freeze. Keep vial in outer carton until use.
Shelf Life24 months (unopened, dry powder)

Product Overview

Omeprazole Powder for Injection 40mg is a sterile, lyophilized formulation of omeprazole sodium intended for intravenous administration after reconstitution. Each vial contains omeprazole sodium equivalent to 40mg of omeprazole as a white to off-white lyophilized cake or powder. Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system (the proton pump) at the secretory surface of gastric parietal cells. It is widely used in the management of acid-related gastrointestinal disorders where oral therapy is not feasible or when rapid acid suppression is required.

Omeprazole Powder for Injection 40mg: What the Published Guidance Says

Acid-suppression and antiemetic agents supplied as injectables and orals, including the proton-pump inhibitor and the two antiemetics carried on the WHO Model List.

Omeprazole Powder for Injection 40mg sits in the GI & Antiemetics range. The notes below are the ones that most often change a specification, a label or a tender submission.

  • Omeprazole is the listed proton-pump inhibitor Section 17.1 of the Model List carries omeprazole as powder for injection 40 mg in vial, powder for oral liquid, and solid oral dosage forms of 10, 20 and 40 mg, for gastro-oesophageal reflux disease. It was first added in 2009. Therapeutic alternatives are the A02BC proton-pump inhibitor subgroup, excluding combinations. The 2025 revision replaced the 20 mg and 40 mg oral-liquid sachets with 1 mg/mL and 4 mg/mL powders for oral liquid. WHO eEML — Omeprazole
  • Dexamethasone doubles as an antiemetic Dexamethasone injection 4 mg/mL is listed in the antiemetic section as well as under antiallergic and palliative-care medicines — useful context when building a chemotherapy-support or post-operative nausea kit. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
  • The antiemetics and their age limits Section 17.2 carries metoclopramide injection 5 mg/mL in 2 mL ampoule and 10 mg tablets, with a Model List note that it is not for use in neonates. Ondansetron is listed as injection 2 mg base/mL in 2 mL ampoule, oral liquid 4 mg base/5 mL, and solid oral forms equivalent to 4, 8 and 24 mg base, indicated above one month of age. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)

These points are quoted because they shape how Omeprazole Powder for Injection 40mg is specified, labelled and purchased — including strength selection, pack size and the artwork wording. Confirm each one against the approved product information in your market before finalising a purchase order.

Ordering Parameters for Omeprazole Powder for Injection 40mg

Product NameOmeprazole Powder for Injection
Specification40mg per vial
Dosage FormSterile Lyophilized Powder for Solution for Intravenous Injection / Infusion
Active IngredientOmeprazole (as Omeprazole Sodium)
Pharmacological ClassProton Pump Inhibitor (PPI) / Gastric Acid Secretion Inhibitor
Route of AdministrationIntravenous injection (slow, over at least 2 to 5 minutes), or intravenous infusion (after further dilution, over 20 to 30 minutes). NOT for intramuscular or subcutaneous injection.
StorageStore below 25°C, protected from light and moisture. Do not freeze. Keep vial in outer carton until use.
Therapeutic groupGI & Antiemetics — GI & Antiemetics
ManufacturerSinophare Bio-technology Co., Ltd. (GMP, China)
Documentation suppliedCOA, HPLC/GC data, stability data, dossier package

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Cimetidine Injection 2mL:400mg Ampoule, Metoclopramide Injection 10mg/2mL, Ondansetron Injection 4mg/2mL, Omeprazole 20mg Capsules, Ranitidine 150mg Capsules.

Pharmacopoeial Standard, Release Testing & COA

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Omeprazole Powder for Injection 40mg is released against the pharmacopoeial monograph named on your order (USP, EP, BP or CP). Where no monograph exists for the exact presentation, the specification is agreed with you in writing before manufacture and is attached to the certificate of analysis.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

The quality control package for the marketed pack covers:

  • Testing for dissolution or release profile (solid oral forms)
  • Testing for uniformity of dosage units
  • Testing for water content and pH where applicable
  • Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
  • Testing for microbial limits and preservative efficacy (multi-dose presentations)
  • Testing for heavy metals and elemental impurities

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

Packing, Labelling Languages & Export Paperwork

  • Pack size: 40mg lyophilized powder in glass vial with rubber stopper and aluminum flip-off cap. Non-standard pack sizes can be quoted against your artwork.
  • Storage: Store below 25°C, protected from light and moisture. Do not freeze. Keep vial in outer carton until use..
  • Shelf life: 24 months (unopened, dry powder). Stability data for the marketed pack is included in the dossier.
  • Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
  • Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.

Marketing Authorisation & Tender Support

Sinophare Bio-technology Co., Ltd. holds DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. That registration identifies the legal manufacturer on the certificate of analysis, the GMP certificate and the documents filed with your national medicines authority.

  • Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
  • Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
  • Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
  • Batch manufacturing and packaging records released for inspection on request during supplier audits.
  • Re-test or renewal support when the marketing authorisation comes up for variation or renewal.

This page describes Omeprazole Powder for Injection 40mg as a product of the gastrointestinal and antiemetic medicines named in the WHO Model List family. A WHO or national listing is a supply-context fact, not an approval in your market; marketing authorisation remains specific to each country.

Omeprazole Powder for Injection 40mg: Common Procurement Questions

What pack size is available for Omeprazole Powder for Injection 40mg?

The reference pack is 40mg lyophilized powder in glass vial with rubber stopper and aluminum flip-off cap. Non-standard blister, bottle and carton configurations are quoted against your artwork, matched to the stability data already held for the presentation.

What documentation comes with a shipment of Omeprazole Powder for Injection 40mg?

Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 24 months.

Does the batch documentation for Omeprazole Powder for Injection 40mg support a registration filing?

Each batch ships with a certificate of analysis covering description, identification, assay and related substances, plus stability data for the marketed pack and the GMP certificate of the manufacturing site. Shelf life: 24 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.

Do you supply omeprazole for injection?

Yes — omeprazole 40 mg powder for injection in vial, matching the presentation in the Model List, supplied with approved reconstitution guidance.

Is omeprazole on the WHO Essential Medicines List?

Yes — section 17.1 lists omeprazole as powder for injection 40 mg in vial, powder for oral liquid and solid oral forms of 10, 20 and 40 mg.

Products Commonly Ordered with Omeprazole Powder for Injection 40mg

Browse the full GI & Antiemetics range; all Injectables; the complete product catalogue.

Request a Quotation for Omeprazole Powder for Injection 40mg

Send the specification, pack size, quantity and destination market for Omeprazole Powder for Injection 40mg 40mg and we will confirm availability, lead time and documentation. Tender quantities and registration samples are handled on the same quotation.

Request a quotation

Sources & Regulatory Notes

Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

<< return to products